Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

BACKGROUND: Subcutaneous peginterferon beta-1a provided clinical benefits at Year 1 (placebo-controlled period) of the 2-Year Phase 3 ADVANCE study in relapsing-remitting multiple sclerosis (RRMS). Here we report the effect of peginterferon beta-1a on brain magnetic resonance imaging (MRI) lesions,...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Douglas L, Calabresi, Peter A, Kieseier, Bernd C, Sheikh, Sarah I, Deykin, Aaron, Zhu, Ying, Liu, Shifang, You, Xiaojun, Sperling, Bjoern, Hung, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311432/
https://www.ncbi.nlm.nih.gov/pubmed/25551571
http://dx.doi.org/10.1186/s12883-014-0240-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311432/
https://www.ncbi.nlm.nih.gov/pubmed/25551571
http://dx.doi.org/10.1186/s12883-014-0240-x

Ejemplares similares